Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model

Retrovirology

Volumn 9, Issue , 2012, Pages

  Page, Mark ^a   Stebbings, Richard ^a   Berry, Neil ^a   Hull, Robin ^a   Ferguson, Deborah ^a   Davis, Leanne ^a   Duffy, Laura ^a   Elsley, William ^a   Hall, Joanna ^a   Ham, Claire ^a   Hassall, Mark ^a   Li, Bo ^a   Mee, Edward T ^a   Quartey Papafio, Ruby ^a   Rose, Nicola J ^a   Mathy, Nathalie ^b   Voss, Gerald ^b   Stott, E J ^a   Almond, Neil ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b GSK   (Belgium)

Author keywords

Cynomolgus macaque; Envelope HIV 1 vaccine; Heterologous challenge; Macaque model; Protection; Recombinant gp120; SHIV

Indexed keywords

ANTISERUM; ASO2A ADJUVANT; HUMAN IMMUNODEFICIENCY VIRUS 1 RECOMBINANT GLYCOPROTEIN GP 120 VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; MACACA FASCICULARIS; NONHUMAN; PROTEIN EXPRESSION; RECIPIENT; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VACCINATION; VIRUS DETECTION; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS TITRATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; IMMUNE SERA; IMMUNIZATION; MACACA FASCICULARIS; NEUTRALIZATION TESTS; RNA, VIRAL; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; TIME FACTORS; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 84865178935     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-56     Document Type: Article

References (42)

1. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619. 10.1038/nature07352, 2572109, 18833271.
2. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006, 6:930-939. 10.1038/nri1959, 17124514.
3. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33:542-554. 10.1016/j.immuni.2010.09.011, 3031162, 21029964.
4. Cohen J. A setback and an advance on the AIDS vaccine front. Science 2003, 300:28-29.
5. McCarthy M. AIDS vaccine fails in Thai trial. Lancet 2003, 362:1728.
6. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, Van-áGriensven F. Randomized, DoubleΓÇÉBlind, PlaceboΓÇÉControlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIVΓÇÉ1 Vaccine among Injection Drug Users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671. 10.1086/508748, 17109337.
7. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 2009, 361:2209-2220. 10.1056/NEJMoa0908492, 19843557.
8. Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS- like disease after in vivo passage in rhesus monkeys. J Virol 1996, 70:6922-6928. 190741, 8794335.
9. Stott EJ, Almond N, Kent K, Walker B, Hull R, Rose J. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J Gen Virol 1998, 79:423-432.
10. Mooij P, van der Kolk M, Bogers WM, Ten Haaft P, Van Der Meide P, Almond N. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 1998, 12:F15-F22. 1-1-1998, 10.1097/00002030-199805000-00002, 9543435.
11. Ranjbar S, Jones S, Stott EJ, Almond N. The Construction and Evaluation of SIV/HIV Chimeras That Express the Envelope of European HIV Type 1 Isolates. AIDS Research and Human Retroviruses 1997, 13:797-800. 10.1089/aid.1997.13.797, 9171224.
12. Mooij P, Bogers WMJM, Oostermeijer H, Koornstra W, Ten Haaft PJF, Verstrepen BE. Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J Virol 2000, 74:4017-4027. 10.1128/JVI.74.9.4017-4027.2000, 111915, 10756013.
13. Luciw PA, Pratt-Lowe E, Shaw KE, Levy JA, Cheng-Mayer C. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci 1995, 92:7490-7494. 10.1073/pnas.92.16.7490, 41365, 7638218.
14. Sauermann U, Schneider J, Mous J, Brunckhorst U, Schedel I, Jentsch KD. Molecular cloning and characterization of a german HIV-1 Isolate. AIDS Research and Human Retroviruses 1990, 6:813-823. 10.1089/aid.1990.6.813, 2364020.
15. Voss G, Manson K, Montefiori D, Watkins DI, Heeney J, Wyand M. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 2003, 77:1049-1058. 10.1128/JVI.77.2.1049-1058.2003, 140820, 12502820.
16. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22:339-348. 10.1097/QAD.0b013e3282f3ca57, 18195560.
17. Rasmussen RA, Ong H, Song R, Chenine A-L, Ayash-Rashkovsky M, Hu S-L. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges AIDS. AIDS 2011, 21:1841-1848.
18. Ellenberger D, Otten RA, Li B, Aidoo M, Rodriguez IV, Sariol CA. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology 2006, 352:216-225. 10.1016/j.virol.2006.04.005, 16725169.
19. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, advance online publication.
20. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527. 10.1038/nature10003, 3102768, 21562493.
21. Dunn CS, Beyer C, Kieny MP, Gloeckler L, Schmitt D, Gut JP. High Viral Load and CD4 Lymphopenia in Rhesus and Cynomolgus Macaques Infected by a Chimeric Primate Lentivirus Constructed Using theenv, rev, tat, andvpuGenes from HIV-1 Lai. Virology 1996, 223:351-361. 10.1006/viro.1996.0486, 8806570.
22. Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. JAIDS Journal of Acquired Immune Deficiency Syndromes 1992, 5:639-646.
23. Heeney JL, Plotkin SA. Immunological correlates of protection from HIV infection and disease. Nat Immunol 2006, 7:1281-1284. 10.1038/ni1206-1281, 17110946.
24. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J. on bo: Antibody-Based HIV-1 vaccines: recent developments and future directions. PLoS Med 2007, 4:e348. 10.1371/journal.pmed.0040348, 2100141, 18052607.
25. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008, 14:617-621. 10.1038/nm.f.1759, 18535579.
26. McCormack S, Tilzey A, Carmichael A, Gotch F, Kepple J, Newberry A. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 2000, 18:1166-1177. 10.1016/S0264-410X(99)00388-6, 10649617.
27. Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007, 25:510-518. 10.1016/j.vaccine.2006.07.050, 17049679.
28. Leroux-Roels I, Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 2010, 28:7016-7024. 10.1016/j.vaccine.2010.08.035, 20728522.
29. Mee ET, Berry N, Ham C, Aubertin A, Lines J, Hall J. Mhc haplotype M3 is associated with early control of SHIVsbg infection in Mauritian cynomolgus macaques. Tissue Antigens 2010, 76:223-229. 10.1111/j.1399-0039.2010.01500.x, 20403147.
30. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002, 76:2123-2130. 10.1128/jvi.76.5.2123-2130.2002, 153825, 11836389.
31. Budde M, Wiseman R, Karl J, Hanczaruk B, Simen B, O ÇÖConnor D. Characterization of Mauritian cynomolgus macaque major histocompatibility complex class I haplotypes by high-resolution pyrosequencing. Immunogenetics 2010, 62:773-780. 10.1007/s00251-010-0481-9, 3077881, 20882385.
32. O'Connor S, Blasky A, Pendley C, Becker E, Wiseman R, Karl J. Comprehensive characterization of MHC class II haplotypes in Mauritian cynomolgus macaques. Immunogenetics 2007, 59:449-462. 10.1007/s00251-007-0209-7, 2836927, 17384942.
33. Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, Wolf H. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol 1987, 61:570-578. 253982, 2433466.
34. Wilkinson TM, Li CKF, Chui CSC, Huang AKY, Perkins M, Liebner JC. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18:274-280. 10.1038/nm.2612, 22286307.
35. Perlaza BL, Valencia AZ, Zapata C, Castellanos A, Sauzet JP, Blanc C. Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides. Eur J Immunol 2008, 38:2610-2615. 10.1002/eji.200738055, 18792413.
36. Groenink M, Andeweg AC, Fouchier RA, Broersen S, van der Jagt RC, Schuitemaker H. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J Virol 1992, 66:6175-6180. 283667, 1527855.
37. Berry N, Stebbings R, Ferguson D, Ham C, Alden J, Brown S. Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol 2008, 89:2240-2251. 10.1099/vir.0.2008/001693-0, 18753233.
38. Stott EJ, Taffs F, Kitchin P, Chan WL, Mills KHG, Page M. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet 1990, 336:1538-1541. 10.1016/0140-6736(90)93310-L, 1979369.
39. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312. 10.1038/nature01470, 12646921.
40. Berglund P, Quesada-Rolander M, Putkonenen P, Biberfeld G, Thorstensson R, Liljestrum P. outcome of immunization of cynomolgus monkeys with recombinant semliki forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Research and Human Retroviruses 1997, 13:1487-1495. 10.1089/aid.1997.13.1487, 9390747.
41. Wiseman RW, Wojcechowskyj JA, Greene JM, Blasky AJ, Gopon T, Soma T. Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from mauritius. J Virol 2007, 81:349-361. 10.1128/JVI.01841-06, 1797269, 17035320.
42. Mee E, Berry N, Ham C, Sauermann U, Maggiorella M, Martinon F. Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques. Immunogenetics 2009, 61:327-339. 10.1007/s00251-009-0369-8, 19337730.